Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
企業コードVVOS
会社名Vivos Therapeutics Inc
上場日Dec 11, 2020
最高経営責任者「CEO」Mr. R. Kirk Huntsman
従業員数109
証券種類Ordinary Share
決算期末Dec 11
本社所在地7921 Southpark Plaza,
都市LITTLETON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号80120
電話番号18669084867
ウェブサイトhttps://vivos.com/
企業コードVVOS
上場日Dec 11, 2020
最高経営責任者「CEO」Mr. R. Kirk Huntsman
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし